[go: up one dir, main page]

WO2008149965A1 - ピリドン化合物 - Google Patents

ピリドン化合物 Download PDF

Info

Publication number
WO2008149965A1
WO2008149965A1 PCT/JP2008/060417 JP2008060417W WO2008149965A1 WO 2008149965 A1 WO2008149965 A1 WO 2008149965A1 JP 2008060417 W JP2008060417 W JP 2008060417W WO 2008149965 A1 WO2008149965 A1 WO 2008149965A1
Authority
WO
WIPO (PCT)
Prior art keywords
good
receptor agonist
group
pyridone
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/060417
Other languages
English (en)
French (fr)
Inventor
Takashi Kamikubo
Fukushi Hirayama
Masanori Miura
Yuriko Komiya
Takao Okuda
Keisuke Maki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to MX2009013355A priority Critical patent/MX2009013355A/es
Priority to CA2693552A priority patent/CA2693552A1/en
Priority to US12/663,246 priority patent/US20100179137A1/en
Priority to CN200880018253A priority patent/CN101679262A/zh
Priority to EP08765230A priority patent/EP2154130A4/en
Priority to JP2009517901A priority patent/JPWO2008149965A1/ja
Publication of WO2008149965A1 publication Critical patent/WO2008149965A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

【解決手段】発明者等は、EP4受容体アゴニストについて鋭意検討した結果、ピリドン環の１位がカルボキシル基などの酸性基を有する基で置換され、６位が低級アルキル、低級アルキレン、エーテル又はチオエーテルを介して芳香環基と結合していることを特徴とする新規なピリドン化合物が、良好なEP4受容体アゴニスト作用を有することを確認し、本発明を完成した。本発明化合物は、良好なEP4受容体アゴニスト作用、及びラット後肢血流増加作用を有することから、医薬、殊に末梢動脈閉塞症の治療剤として有用である。
PCT/JP2008/060417 2007-06-07 2008-06-06 ピリドン化合物 Ceased WO2008149965A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2009013355A MX2009013355A (es) 2007-06-07 2008-06-06 Compuesto de piridona.
CA2693552A CA2693552A1 (en) 2007-06-07 2008-06-06 Pyridone compound
US12/663,246 US20100179137A1 (en) 2007-06-07 2008-06-06 Pyridone compound
CN200880018253A CN101679262A (zh) 2007-06-07 2008-06-06 吡啶酮化合物
EP08765230A EP2154130A4 (en) 2007-06-07 2008-06-06 pyridone
JP2009517901A JPWO2008149965A1 (ja) 2007-06-07 2008-06-06 ピリドン化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-151243 2007-06-07
JP2007151243 2007-06-07

Publications (1)

Publication Number Publication Date
WO2008149965A1 true WO2008149965A1 (ja) 2008-12-11

Family

ID=40093769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060417 Ceased WO2008149965A1 (ja) 2007-06-07 2008-06-06 ピリドン化合物

Country Status (9)

Country Link
US (1) US20100179137A1 (ja)
EP (1) EP2154130A4 (ja)
JP (1) JPWO2008149965A1 (ja)
KR (1) KR20100031725A (ja)
CN (1) CN101679262A (ja)
CA (1) CA2693552A1 (ja)
MX (1) MX2009013355A (ja)
TW (1) TW200911245A (ja)
WO (1) WO2008149965A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154190A1 (ja) 2008-06-17 2009-12-23 アステラス製薬株式会社 ピリドン化合物
US8592629B2 (en) 2010-07-12 2013-11-26 Pfizer Limited Sulfonamide derivatives as Nav 1.7 inhibitors
US8685977B2 (en) 2010-07-12 2014-04-01 Pfizer Limited Chemical compounds
US8772293B2 (en) 2010-07-09 2014-07-08 Pfizer Limited Chemical compounds
JP2022031717A (ja) * 2014-12-19 2022-02-22 ガイストリッヒ・ファルマ・アーゲー オキサチアジン様化合物を作製する方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
CN104797555B (zh) * 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
HK1213476A1 (zh) 2013-03-14 2016-07-08 基因泰克公司 取代的三唑並吡啶及其使用方法
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
PE20180575A1 (es) 2015-05-22 2018-04-04 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
BR112018006189A2 (pt) 2015-09-28 2018-10-09 Genentech Inc compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535980A1 (en) 1991-10-02 1993-04-07 Sumitomo Chemical Company, Limited 2-Pyridone derivatives, a process for their preparation and their use as fungicides
JPH05194398A (ja) * 1991-10-02 1993-08-03 Sumitomo Chem Co Ltd アクリル酸誘導体、その製造法およびそれを有効成分として含有する植物病害防除剤
WO2001087842A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
WO2005116010A1 (en) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
WO2006014207A1 (en) 2004-07-02 2006-02-09 Allergan, Inc. Prostaglandin analogs
WO2006052630A1 (en) 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006080323A1 (ja) 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ６員環化合物及びその用途
JP2006520758A (ja) * 2003-03-26 2006-09-14 メルク フロスト カナダ リミテツド Ｅｐ４受容体作動薬としてのプロスタグランジン類縁体
JP2006526637A (ja) * 2003-06-02 2006-11-24 アラーガン、インコーポレイテッド 医薬としての８−アザプロスタグランジンカーボネートおよびチオカーボネート類似体
WO2007014454A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
WO2007014462A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526337A (ja) * 2003-05-09 2006-11-16 松下電器産業株式会社 再生装置及びダイジェスト再生方法
KR20110017884A (ko) * 2008-06-17 2011-02-22 아스텔라스세이야쿠 가부시키가이샤 피리돈 화합물

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535980A1 (en) 1991-10-02 1993-04-07 Sumitomo Chemical Company, Limited 2-Pyridone derivatives, a process for their preparation and their use as fungicides
JPH05194398A (ja) * 1991-10-02 1993-08-03 Sumitomo Chem Co Ltd アクリル酸誘導体、その製造法およびそれを有効成分として含有する植物病害防除剤
WO2001087842A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
JP2006520758A (ja) * 2003-03-26 2006-09-14 メルク フロスト カナダ リミテツド Ｅｐ４受容体作動薬としてのプロスタグランジン類縁体
JP2006526637A (ja) * 2003-06-02 2006-11-24 アラーガン、インコーポレイテッド 医薬としての８−アザプロスタグランジンカーボネートおよびチオカーボネート類似体
WO2005116010A1 (en) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
WO2006014207A1 (en) 2004-07-02 2006-02-09 Allergan, Inc. Prostaglandin analogs
WO2006052630A1 (en) 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006080323A1 (ja) 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ６員環化合物及びその用途
WO2007014454A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
WO2007014462A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Research and Development", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, pages: 163 - 198
"Protective Groups in Organic Synthesis", 2007
AM. J. PHYSIOL., vol. 279, 2000, pages F755
BIOCHEM. PHARMACOL., vol. 61, 2001, pages 1153
BR. J. PHARMACOL., vol. 2001, no. 134, pages 313
CIRCULATION, vol. 104, 2001, pages 1176
EUR. J. VASE. ENDOVASC. SURG, vol. 33, no. 1, 2007, pages L
GASTROENTEROLOGY, vol. 117, 1999, pages 1352
KID. INT., vol. 56, 1999, pages 589
PHSIOL. REV., vol. 79, 1999, pages 1193
PROC. NATL. ACAD. SCI. U.S.A., vol. 99, 2002, pages 4580
PROG. MED., vol. 5, 1985, pages 2157 - 2161
PROSTAGLANDINS, vol. 52, 1996, pages 175
See also references of EP2154130A4

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154190A1 (ja) 2008-06-17 2009-12-23 アステラス製薬株式会社 ピリドン化合物
US8772293B2 (en) 2010-07-09 2014-07-08 Pfizer Limited Chemical compounds
US8592629B2 (en) 2010-07-12 2013-11-26 Pfizer Limited Sulfonamide derivatives as Nav 1.7 inhibitors
US8685977B2 (en) 2010-07-12 2014-04-01 Pfizer Limited Chemical compounds
JP2022031717A (ja) * 2014-12-19 2022-02-22 ガイストリッヒ・ファルマ・アーゲー オキサチアジン様化合物を作製する方法
JP7449913B2 (ja) 2014-12-19 2024-03-14 ガイストリッヒ・ファルマ・アーゲー オキサチアジン様化合物を作製する方法

Also Published As

Publication number Publication date
CN101679262A (zh) 2010-03-24
KR20100031725A (ko) 2010-03-24
MX2009013355A (es) 2010-02-22
EP2154130A1 (en) 2010-02-17
CA2693552A1 (en) 2008-12-11
EP2154130A4 (en) 2011-09-07
TW200911245A (en) 2009-03-16
US20100179137A1 (en) 2010-07-15
JPWO2008149965A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2008149965A1 (ja) ピリドン化合物
MX2010004503A (es) Compuesto de oxadiazolidinediona.
WO2008016692A3 (en) Chemical compounds
CA2661102C (en) Thiophene derivatives as s1p1/edg1 receptor agonists
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
WO2007135527A3 (en) Benzimidazolyl compounds
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
WO2007146122A3 (en) Tetrahydropyrido[3,4-d]pyrimidines and related analogues
WO2010122980A8 (ja) 新規甲状腺ホルモンβ受容体作動薬
EP2255822A4 (en) USE OF THE EFFECTIVE SECTION OF ALKALOIDS FROM RAMULUS MORI FOR THE PREPARATION OF A HYPOGLYKEMIC AGENT
ATE459338T1 (de) Formulierungen für benzimidazolylpyridylether
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
WO2009054390A1 (ja) チアゾリジンジオン化合物
WO2006086488A3 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2008097819A3 (en) Chemical compounds
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
WO2007098964A3 (en) Pyrrazole derivatives as sigma receptors antagonists
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
MY163762A (en) Therapeutic agent for chronic renal failure
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008014361A3 (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880018253.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765230

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009517901

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008765230

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12663246

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2693552

Country of ref document: CA

Ref document number: 7196/CHENP/2009

Country of ref document: IN

Ref document number: MX/A/2009/013355

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107000252

Country of ref document: KR

Kind code of ref document: A